Search Within

Genitourinary Oncology Service

  1. "2024"
Formats
  1. Meeting Abstract (148)
  2. Journal Article (114)
  3. Review (15)
  4. Research Letter (6)
  5. Editorial (5)
  6. Guidelines (2)
  7. Book Section (1)
  8. Conference Paper (1)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Solid Tumor Oncology Division (294)
  2. Department of Medicine (292)
  3. GSK Faculty (64)
  4. Epidemiology and Biostatistics (63)
  5. Human Oncology and Pathogenesis Program (60)
  6. Graduate Medical Education (58)

More Groups

People
  1. Michael Morris (50)
  2. Robert Motzer (49)
  3. Gopakumar Iyer (41)
  4. David Solit (38)
  5. Jonathan Rosenberg (36)
  6. Darren Feldman (24)

More People

Years
  1. 2024 (294)
Publications
  1. Journal of Clinical Oncology (91)
  2. Annals of Oncology (23)
  3. Clinical Cancer Research (12)
  4. European Urology (12)
  5. European Journal of Cancer (10)
  6. Urologic Oncology: Seminars and Original Investigations (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (95)
  2. Oxford University Press (42)
  3. Elsevier Inc. (29)
  4. Elsevier Science, Inc. (22)
  5. American Association for Cancer Research (21)
  6. Nature Publishing Group (11)

More Publishers

Results (294)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of prior chemotherapy on response to second-line pembrolizumab in urothelial cancer: Exploratory analysis of the phase 3 KEYNOTE-045 trial
    Journal Article

    de Wit, R.; Vaughn, D. J.; Fradet, Y.; Fong, L.; Climent, M. A.; Necchi, A.; Petrylak, D. P.; Gerritsen, W. R.; Gurney, H.; Quinn, D. I.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • The effect of biosimilar entry on biologic drug prices in Medicare part B
    Meeting Abstract

    Winn, A.; Abdelaziz, A.; Dusetzina, S. B.; Mitchell, A. P.
    Value in Health (2024)

    Fulltext@MSK | Save
  • New treatment approaches in muscle-invasive bladder cancer
    Book Section

    Gupta, A.; Rosenberg, J. E.
    In Knowles, M. A.; Dyrskjøt, L. (Eds.) Biology of Bladder Cancer: From Molecular Insights to Clinical Strategies (2024)

    Fulltext@MSK | Save
  • Surgical outcomes and genomic insights of nonclear cell renal cell carcinoma with synchronous and metachronous nodal disease
    Journal Article

    Eismann, L.; Zucker, M.; Dawidek, M. T.; Reese, S. W.; Calderon, L. P.; Aulitzky, A.; Stief, C. G.; Coleman, J. A.; Kotecha, R. R.; Carlo, M.; more...
    Urology Practice (2024)

    Fulltext@MSK | Save
  • Characterising the contribution of rare protein-coding variants to prostate cancer risk and severity in 36,866 cases
    Meeting Abstract

    Mitchell, J.; Camacho, N.; Shea, P. R.; Stopsack, K.; Joseph, V.; Burren, O.; Penney, K.; Berchuck, J.; Wang, Q. L.; Goldstein, D.; more...
    European Journal of Human Genetics (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution
    Meeting Abstract

    Apolo, A. B.; Ballman, K.; Sonpavde, G. P.; Berg, S.; Kim, W.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D.; Grivas, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Meeting Abstract

    Powles, T. B.; van der Heijden, M. S.; Gupta, S.; Perez Valderrama, B.; Galsky, M. D.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Maroto Rey, J. P.; Vulsteke, C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2- expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
    Meeting Abstract

    Galsky, M. D.; Koshkin, V. S.; Campbell, M. T.; Drakaki, A.; Bowman, I.; Rose, A. A. N.; Brown, J. R.; Aragon-Ching, J. B.; Gadde, S.; Harandi, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Rosenberg, J. E.; Petrylak, D. P.; Flaig, T.; Hoimes, C. J.; Gupta, S.; O'Donnell, P. H.; Mar, N.; Friedlander, T.; Tagawa, S. T.; Bilen, M. A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save